Italy's antitrust regulator opened an investigation into Biogen on May 27, 2024 [1], over the alleged abuse of a dominant market position.
The probe focuses on whether the U.S. company and its subsidiary, Biogen Italia, intentionally hindered the sale of a competing multiple sclerosis drug produced by Sandoz. If the regulator finds that Biogen used its market power to exclude rivals, it could face significant penalties and be forced to change its commercial strategies within the European Union.
The investigation was announced in Milan by the Italy Competition Authority, known as AGCM [1]. The regulator said it is examining whether Biogen's actions created an unfair environment that prevented Sandoz from effectively entering or competing in the Italian pharmaceutical market [1].
Multiple sclerosis treatments are high-stakes products with significant costs to national healthcare systems. When a single provider dominates the market, the lack of competition can lead to higher prices and limited options for patients. The AGCM is tasked with ensuring that the Italian market remains open to generic, or biosimilar, alternatives that can lower costs.
Biogen has not issued a public statement regarding the specific findings of the AGCM at this time. The investigation will look into the company's internal practices and its interactions with healthcare providers to determine if the exclusion of Sandoz was a deliberate corporate strategy [1].
This case reflects a broader trend of European regulators scrutinizing the pricing and distribution tactics of global pharmaceutical firms. The outcome of the probe will depend on whether the AGCM can prove that Biogen's conduct crossed the line from aggressive competition to illegal market foreclosure [1].
“Italy's antitrust regulator opened an investigation into Biogen on May 27, 2024”
This investigation signals Italy's commitment to reducing pharmaceutical monopolies to lower public healthcare spending. By targeting the exclusion of Sandoz's drug, the AGCM is attempting to create a precedent that protects the entry of biosimilars, which are typically cheaper than original brand-name medications, thereby increasing patient access and reducing the financial burden on the state.
